COSMOS: A 2-Cohort, Phase 2 Study of MOR208 plus Idelalisib or Venetoclax in Patients with R/R CLL/SLL Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia

There are limited treatment options for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who discontinue treatment with ibrutinib due to disease progression, transformation, or intolerance, and these patients have a very poor prognosis. In a phase 1 study, the Fc-enhanced, humanized, CD19 antibody MOR208 showed promising activity in patients with R/R CLL/small lymphocytic lymphoma (SLL). Furthermore, preclinical models suggest that the clinical activity of MOR208 may be complementary to idelalisib (an inhibitor of PI3Kδ) and venetoclax (an inhibitor of BCL-2), both approved for the treatment of CLL.

To evaluate the efficacy and safety of MOR208 combined with idelalisib or venetoclax, investigators initiated a 2-cohort, phase 2 study in adult patients with R/R CLL/SLL. To be included in the study, patients were required to receive prior treatment or demonstrate intolerance to treatment with a Bruton’s tyrosine kinase inhibitor, have Eastern Cooperative Oncology Group performance status of 0 to 2, and maintain adequate organ function.

Each study cohort is expected to include 120 patients. Patients will be treated with intravenous MOR208 12 mg/kg (weekly for the first 3 months, every second week for the next 3 months, and monthly thereafter) in combination with oral idelalisib 150 mg twice daily or venetoclax administered on a weekly ramp-up dosing schedule to the recommended daily dose of 400 mg. Treatment will continue for a maximum of 24 cycles or until disease progression. The primary end point is overall response rate based on independent review. Secondary and exploratory end points include progression-free survival and overall survival, time to progression, duration of response, safety, MOR208 immunogenicity and pharmacokinetics, quality of life, and minimal residual disease negativity. The study is expected to shed light on potential treatment options in a difficult-to-treat population of patients with R/R CLL and R/R SLL.

Wendtner CM, et al. ASCO Abstract TPS7567.

Related Items
iFCG for Previously Untreated Patients with CLL with Mutated IGHV and Non-Del(17p)
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Phase 1 Dose Escalation of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle-Cell Lymphoma, and Follicular Lymphoma
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL Intolerant to Prior Bruton’s Tyrosine Kinase or PI3Kδ Inhibitor Therapy
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas
Conference Correspondent published on June 8, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Last modified: June 7, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME